Activities of Nicola CAPUTO related to 2014/2040(BUD)
Plenary speeches (2)
General budget of the European Union for the financial year 2015 - all sections (A8-0014/2014 - Eider Gardiazabal Rubial, Monika Hohlmeier) IT
General budget of the European Union for the financial year 2015 - all sections (debate) IT
Amendments (2)
Amendment 8 #
Draft opinion
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Recalls that Horizon 2020 will contribute to objectives in the remit of this committee with research projects in the areas of climate, health, environment and in particular the production of renewable energy through innovative solutions; affirms its commitment to monitor the alignment of the projects with the corresponding objectives and the progress of the implementation;
Amendment 12 #
Draft opinion
Paragraph 14
Paragraph 14
14. Notes, that the contribution to the European Medicines Agency for 2015, as requested by the Agency and as adopted by the Commission amounts to EUR €31,516 million; i. Is aware that to this amount, the 2013 outturn of EUR €1,499 million needs to be added, reaching a total contribution of EUR €33,015 million in 2015; points out that the proposed contribution does not cover any additional contribution relating to the implementation of the Pharmacovigilance legislation, as the costs of this activity are to be covered by fees; recalls that Regulation (EU) No 658/2014 of the European Parliament and of the Council1 entered into force in July 2014 and that the Agency will have to adapt its existing resources to cover the Pharmacovigilance activities;Pharmacovigilance activities stresses that the European Medicines Agency is one of the industry- driven agencies which, in the last four years, has not received one additional post for the implementation of the Pharmacovigilance legislation resulting in a slow-down of handling files; will therefore not accept the foreseen cut of 5% applied to the whole agency staff; ____________________ 1 Regulation (EU) No 658/2014 of the European Parliament and of the Council of 15 May 2014 on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use (OJ L 189, 27.6.2014, p. 112).